Abstract
The Vesicular Acetylcholine Transporter (VAChT) is found throughout the cholinergic nervous system and is responsible for transporting Acetylcholine (ACh) into synaptic vesicles for storage. Deterioration of cholinergic neurotransmission is a known pathophysiological hallmark of Alzheimers disease (AD). Ligands that bind to VAChT – particularly in the brain and CNS where cholinergic neurotransmission is vital for memory and cognitive function – may facilitate the study of cholinergic pathway regulation in the CNS and serve as useful diagnostic agents for AD. Vesamicol was the first VAChT ligand identified, however its poor selectivity has prompted the search for more potent and selective compounds. Numerous structural modifications to the vesamicol scaffold have been explored and several classes of VAChT ligands are highlighted in this review. The affinity and selectivity of these ligands for VAChT and -receptors are discussed.
Keywords: Alzheimer's disease, benzovesamicol, CNS, structure-activity relationship, VAChT, vesamicol
Current Bioactive Compounds
Title: Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Volume: 6 Issue: 3
Author(s): Nicolas Giboureau, Kylee M. Aumann, Corinne Beinat and Michael Kassiou
Affiliation:
Keywords: Alzheimer's disease, benzovesamicol, CNS, structure-activity relationship, VAChT, vesamicol
Abstract: The Vesicular Acetylcholine Transporter (VAChT) is found throughout the cholinergic nervous system and is responsible for transporting Acetylcholine (ACh) into synaptic vesicles for storage. Deterioration of cholinergic neurotransmission is a known pathophysiological hallmark of Alzheimers disease (AD). Ligands that bind to VAChT – particularly in the brain and CNS where cholinergic neurotransmission is vital for memory and cognitive function – may facilitate the study of cholinergic pathway regulation in the CNS and serve as useful diagnostic agents for AD. Vesamicol was the first VAChT ligand identified, however its poor selectivity has prompted the search for more potent and selective compounds. Numerous structural modifications to the vesamicol scaffold have been explored and several classes of VAChT ligands are highlighted in this review. The affinity and selectivity of these ligands for VAChT and -receptors are discussed.
Export Options
About this article
Cite this article as:
Giboureau Nicolas, M. Aumann Kylee, Beinat Corinne and Kassiou Michael, Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease, Current Bioactive Compounds 2010; 6 (3) . https://dx.doi.org/10.2174/157340710793237353
DOI https://dx.doi.org/10.2174/157340710793237353 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry Meta-Analysis of Anticancer Drug Structures - Significance of Their Polar Allylic Moieties
Anti-Cancer Agents in Medicinal Chemistry Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Renovascular Hypertension: Novel Insights
Current Hypertension Reviews Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Challenges and Solutions in the Development of Genomic Biomarker Panels: A Systematic Phased Approach
Current Genomics Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Statin Therapy
Current Pharmaceutical Design MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches
Current Pharmaceutical Biotechnology Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Ethical Aspects of Vegetative and Minimally Conscious States
Current Pharmaceutical Design The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome
Current Cardiology Reviews Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry